Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04956302 · ClinicalTrials.gov registry record · Phase 1
Panobinostat in Combination With Daratumumab, Bortezomib and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma
A Phase 1 study, sponsored by Abdullah Khan.
- Terminated
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT04956302 is a Phase 1 study that was terminated before completion, run by Abdullah Khan. The registered enrollment target is 1 participants.
The verdict
NCT04956302, a Phase 1 study, was terminated before completion, sponsored by Abdullah Khan.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
This phase I trial studies the possible benefits and side effects of adding panobinostat to a combination of daratumumab, bortezomib and dexamethasone in treating patients with multiple myeloma that has come back (relapsed) or has not responded to treatment (refractory). Panobinostat may stop or slow multiple myeloma by blocking the growth of new blood vessels necessary for cancer growth. Giving panobinostat in combination with daratumumab, bortezomib and dexamethasone may work better in treating relapsed/refractory multiple myeloma.
Interventions
- DRUG Dexamethasone
- DRUG Bortezomib
- DRUG Daratumumab and Hyaluronidase-fihj
- DRUG Panobinostat Lactate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2021-09-27 |
| Est. Completion | 2022-06-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04956302
The ClinicalTrials.gov registry entry for NCT04956302 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abdullah Khan, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Dexamethasone is the first listed.
NCT04956302 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04956302 about?
NCT04956302 is a clinical study titled "Panobinostat in Combination With Daratumumab, Bortezomib and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma". This phase I trial studies the possible benefits and side effects of adding panobinostat to a combination of daratumumab, bortezomib and dexamethasone in treating patients with multiple myeloma that has come back (relapsed) or has not responded to treatment (refractory). Panobinostat may stop or slo...
What is the current status of trial NCT04956302?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2021-09-27. Estimated completion is 2022-06-16.
What interventions are being tested in trial NCT04956302?
The interventions under investigation include: Dexamethasone (DRUG), Bortezomib (DRUG), Daratumumab and Hyaluronidase-fihj (DRUG), Panobinostat Lactate (DRUG).
Who is sponsoring clinical trial NCT04956302?
This trial is sponsored by Abdullah Khan, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.